Aug 14, 2020
Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results
May 20, 2020
CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation
May 15, 2020
Titan Pharmaceuticals Reports First Quarter 2020 Financial Results
May 14, 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
May 11, 2020
Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments
May 11, 2020
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 05, 2020
Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
May 01, 2020
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 23, 2020
Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020
Apr 07, 2020
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
Apr 02, 2020
ORIC Pharmaceuticals Appoints Christian V. Kuhlen, M.D., as General Counsel
Apr 01, 2020
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 24, 2020
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T(TM)) Therapies
Mar 16, 2020
Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 05, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Feb 24, 2020
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Feb 12, 2020
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020
Feb 05, 2020
CODA Biotherapeutics Acquires Attenua and Three Clinical Stage Assets
Feb 03, 2020
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer